- Home
- GMS vs OGN Comparison
GMS vs OGN Comparison
Compare GMS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMS
- OGN
- Stock Information
- Founded
- GMS 1971
- OGN 1923
- Country
- GMS United States
- OGN United States
- Employees
- GMS N/A
- OGN N/A
- Industry
- GMS
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- GMS
- OGN Health Care
- Exchange
- GMS Nasdaq
- OGN Nasdaq
- Market Cap
- GMS 3.9B
- OGN 4.7B
- IPO Year
- GMS 2016
- OGN N/A
- Fundamental
- Price
- GMS $99.84
- OGN $15.03
- Analyst Decision
- GMS Buy
- OGN Hold
- Analyst Count
- GMS 8
- OGN 3
- Target Price
- GMS $91.50
- OGN $21.33
- AVG Volume (30 Days)
- GMS 303.2K
- OGN 3.0M
- Earning Date
- GMS 12-05-2024
- OGN 10-31-2024
- Dividend Yield
- GMS N/A
- OGN 7.45%
- EPS Growth
- GMS N/A
- OGN 120.97
- EPS
- GMS 6.07
- OGN 5.04
- Revenue
- GMS $5,540,763,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- GMS $4.35
- OGN $3.13
- Revenue Next Year
- GMS $3.36
- OGN $2.18
- P/E Ratio
- GMS $16.45
- OGN $2.98
- Revenue Growth
- GMS 3.00
- OGN 4.21
- 52 Week Low
- GMS $64.82
- OGN $10.84
- 52 Week High
- GMS $103.56
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- GMS 62.23
- OGN 25.51
- Support Level
- GMS $98.10
- OGN $15.25
- Resistance Level
- GMS $103.56
- OGN $15.85
- Average True Range (ATR)
- GMS 2.25
- OGN 0.68
- MACD
- GMS 0.63
- OGN -0.13
- Stochastic Oscillator
- GMS 74.06
- OGN 4.06
About GMS GMS Inc.
GMS Inc is a distributor of specialty building products including wallboard, suspended ceiling systems, ceilings, steel framing, and other complementary building products. The company serves its products to commercial new construction, commercial repair and remodel, residential new construction, and residential repair and remodel (R&R). Its geographical segment is Central, Midwest, New York, Northeast, Southern, Southeast, Southwest, Western and Canada, and Ames. The company generates maximum revenue from Wallboard products.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.